Please fax both pages of completed form to your team at 866.531.1025.

To reach your team, call toll-free 866.839.2162.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form Dupixent® (dupilumab)



Four simple steps to submit your referral.

New patient Current patient Patient's first name					Diagon municipal comica as	f from and book of all modical
Patient's first name	1	Patient Information				
Preferred patient first name Sex at birth: Male Female Gender identity Pronouns Last 4 digits of SSN Date of birth: Street address Apt # City State Zip	New	patient Current patient				
Sex at birth: Male Female Gender identity Pronouns Last 4 digits of SSN Date of birth Street address Apt # City State Zip Home phone Cell phone Email address Parent/guardian (if applicable) Home phone Cell phone Email address Alternate caregiver/contact Patient's primary language: English Other If other, please specify 2 Prescriber Information All fields must be completed to expedite prescription fulfillment. Date Time Date medication needed Office/clinic/institution name Prescriber's first name Last name Prescriber's first name Frescriber's first name Last name Prescriber's title Office contact and title Office ontact ontact Office on	Patient'	s first name	La	ast name _		Middle initial
Sex at birth: Male Female Gender identity Pronouns Last 4 digits of SSN Date of birth Street address Apt # Cell phone Email address Parent/guardian (if applicable) Home phone Cell phone Email address Parent/guardian (if applicable) Home phone Cell phone Email address Alternate caregiver/contact Home phone Cell phone Email address Alternate caregiver/contact Home phone Cell phone Email address Ok to leave message with alternate caregiver/contact Patient's primary language. English Other If other, please specify 2 Prescriber Information All fields must be completed to expedite prescription fulfillment. Date Time Date medication needed Office/clinic/institution name Prescriber's first name Last name Prescriber's title If NP or PA, under direction of Dr. Office phone Fax NP II License III Office contact and title Office contact and title Office contact and title Office ontact and title Of	Preferre	ed patient first name		Pref	ferred patient last name	
Date of birth Street address						
City State			•			-
Parent/guardian (if applicable)						·
Parent/guardian (if applicable) Home phone	-					
Alternate caregiver/contact Home phone Cell phone Email address			·			
Alternate caregiver/contact Home phone						
Home phone						
OK to leave message with alternate caregiver/contact Patient's primary language: English Other If other, please specify 2 Prescriber Information All fields must be completed to expedite prescription fulfillment. Date	Alternat	e caregiver/contact				
Patient's primary language: English Other If other, please specify Prescriber Information All fields must be completed to expedite prescription fulfillment. Date	Home p	phone C	ell phone		Email address	
Prescriber Information All fields must be completed to expedite prescription fulfillment. Date	OK to	o leave message with alternate caregiv	er/contact			
Date Time Date medication needed Office/clinic/institution name Prescriber info: Prescriber's first name	Patient'	s primary language: English Oth	ner If other, please spec	cify		
Date Time Date medication needed Office/clinic/institution name Prescriber info: Prescriber's first name	0	5 " 16 "				
Office/clinic/institution name Prescriber info: Prescriber's first name	2	Prescriber Information		All field	Is must be completed to	expedite prescription fulfillment.
Office/clinic/institution name Prescriber info: Prescriber's first name	Date	Time		_ Date me	edication needed	
Prescriber's title Fax						
Office phone						
Office contact and titleOffice contact email	Prescrib	er's title	If N	NP or PA, υ	ınder direction of Dr	
Office street address	Office pl	hone Fax _		NPI #	<u> </u>	License #
State	Office co	ontact and title			Office contact ema	il
Infusion location: Patient's home Prescriber's office Infusion site If infusion site, complete information below dotted line: Infusion info: Infusion site name	Office st	reet address				Suite #
Infusion info: Infusion site name	City		State _			Zip
Infusion info: Infusion site name Clinic/hospital affiliation Suite # City State Zip Zip Clinical Information						
Site street address						
City						
Clinical Information CD-10 code (REQUIRED):						
Clinical Information ICD-10 code (REQUIRED): NKDA Known drug allergies Prior anaphylactic reaction: Yes (Reason/date	-					•
ICD-10 code (REQUIRED): NKDA Known drug allergies Prior anaphylactic reaction: Yes (Reason/date	Infusion	site contact	Phone		Fax	Email
NKDA Known drug allergies	3	Clinical Information				
NKDA Known drug allergies	ICD 10 4	anda (REOLUREN).				
Prior anaphylactic reaction: Yes (Reason/date						
Concurrent meds Estimated % BSA involvement Estimated % BSA involvement Concomitant therapies: Short-acting beta agonist Long-acting beta agonist Antihistamines Decongestants Immunotherapy Inhaled corticosteroid Leukotriene modifiers Oral steroids Nasal steroids Other Lab results: History of positive skin OR RAST test to a perennial aeroallergen Pre-treatment steroid dose mg Pre-treatment serum IgE level IU per mL Test date Pre-treatment serum eosinophils cells/mcL and/or sputum eosinophils Date Patient wt kg Date wt obtained MD Specialty (required): Allergist Pulmonologist ENT Primary care Pediatrician Dermatologist Other Prescription type: Naïve/new start Restart Continued therapy Prior therapies: Please fax detailed medication history with dates of use as available. Required by some plan authorization criteria.		8 8) No
Concomitant therapies: Short-acting beta agonist Long-acting beta agonist Antihistamines Decongestants Immunotherapy Inhaled corticosteroid Leukotriene modifiers Oral steroids Nasal steroids Other Lab results: History of positive skin OR RAST test to a perennial aeroallergen Pre-treatment steroid dose mg Pre-treatment serum IgE level IU per mL Test date Pre-treatment serum eosinophils cells/mcL and/or sputum eosinophils Date Patient wt kg Date wt obtained MD Specialty (required): Allergist Pulmonologist ENT Primary care Pediatrician Dermatologist Other Prescription type: Naïve/new start Restart Continued therapy Prior therapies: Please fax detailed medication history with dates of use as available. Required by some plan authorization criteria.		• •				
Inhaled corticosteroid Leukotriene modifiers Oral steroids Nasal steroids Other						
Lab results: History of positive skin OR RAST test to a perennial aeroallergen Pre-treatment steroid dosemg		,		_		.,
Pre-treatment steroid dosemg					S Other	
Pre-treatment serum eosinophils cells/mcL and/or sputum eosinophils Date Patient wt kg Date wt obtained MD Specialty (required): Allergist Pulmonologist ENT Primary care Pediatrician Dermatologist Other Prescription type: Naïve/new start Restart Continued therapy Prior therapies: Please fax detailed medication history with dates of use as available. Required by some plan authorization criteria.					11.1	nor ml. Toot data
Patient wtkg Date wt obtained MD Specialty (required): Allergist Pulmonologist ENT Primary care Pediatrician Dermatologist Other Prescription type: Naïve/new start Restart Continued therapy Prior therapies: Please fax detailed medication history with dates of use as available. Required by some plan authorization criteria.						
MD Specialty (required): Allergist Pulmonologist ENT Primary care Pediatrician Dermatologist Other		·		•	ыпорина	Date
Prescription type: Naïve/new start Restart Continued therapy Prior therapies: Please fax detailed medication history with dates of use as available. Required by some plan authorization criteria.		· ·			istrician Dormatologist	Other
Prior therapies: Please fax detailed medication history with dates of use as available. Required by some plan authorization criteria.				ale red	iatrician Dematologist	Outer
	•	71		available	Required by some plan au	thorization criteria
		•	•			
Topical calcineurin inhibitor Sinus surgery	•		Spical i DE 7 IIIIIDILOI	Sidi Steroit	ao orai illilliullosuppie	1

ledication	Strength / Formulation and Directions	Quantity/Refills
Dupixent® (dupilumab) 200mg/1.14mL pre-filled pen 2-pack Dupixent® (dupilumab) 200mg/1.14mL pre-filled	Starter Dose: Inject 400mg under the skin on Day 1 then 200mg every 2 weeks starting on day 15 and thereafter. Maintenance Dose: Inject 200mg under the skin every 2 weeks. Starter Dose: Inject 600mg under the skin on Day 1 then 300mg	Quantity No refills
syringe 2-pack Dupixent® (dupilumab) 300mg/2mL pre-filled pen 2-pack Dupixent® (dupilumab)	every 2 weeks starting on day 15 and thereafter. Maintenance Dose: Inject 300mg under the skin every 2 weeks. Starter Dose: Inject 600mg under the skin on Day 1 then 300mg every 4 weeks thereafter starting on day 29. Maintenance Dose: Inject 300mg under the skin every 4 weeks.	Maintenance dose: Quantity Refills
300mg/2mL pre-filled syringe 2-pack	For indications without a starter dose: Inject 100mg under the skin every 2 weeks Inject 200mg under the skin every 2 weeks Inject 200mg under the skin every 4 weeks	For indications without a starter dos Quantity Refills
	Inject 300mg under the skin once weekly Inject 300mg under the skin every 2 weeks Inject 300mg under the skin every 4 weeks	Patient weight

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

